High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma DOI
Yuheng Cao, Xue Yin,

Lanrong Wu

et al.

Advanced Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 13, 2025

Abstract Glaucoma is a retinal neurodegenerative disease characterized by progressive apoptosis of ganglion cells (RGCs) and irreversible visual impairment. Current therapies rarely offer direct protection for RGCs, highlighting the need new neuroprotective approaches. Although viral delivery brain‐derived neurotrophic factor (BDNF) has shown potential, concerns about inflammation limited applicability persist. Meanwhile, non‐viral vectors remain inefficient in vivo ocular gene delivery. Here, highly biocompatible nanoplatform—PBAE‐PLGA‐Oligomycin‐pBDNF nanoparticles (PPOB NPs) reported—that co‐delivers oligomycin (an ATP inhibitor) BDNF plasmid to Müller vivo. This nanoplatform attains an unprecedented transfection efficiency 64.26% cells, thereby overcoming limitations monotherapeutic approaches that fail inhibit overproduction attendant inflammatory responses. In chronic hypertension rat model, effectively mitigated RGC damage suppressing cell hyperactivation excessive production under elevated intraocular pressure. Concurrently, it synergistically enhanced expression achieving robust RGCs preservation optic nerve function. These findings underscore promise PPOB NPs as dual‐functional platform, featuring high biocompatibility efficient delivery, multifaceted against glaucoma other diseases.

Language: Английский

Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy DOI

Donya Esmaeilpour,

Matineh Ghomi, Ehsan Nazarzadeh Zare‬

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 12, 2025

RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering (siRNA). However, the clinical application of siRNA-based treatments faces challenges such rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery revolutionized therapy by addressing these limitations, improving stability, tumor-specific targeting, therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance safety precision therapies, offering new opportunities personalized medicine. This review highlights three key innovations nanotechnology-enhanced delivery: artificial intelligence (AI)-driven design, multifunctional nanoparticles combined strategies, biomimetic nanocarriers enhanced biocompatibility. AI-driven utilize machine learning algorithms optimize nanoparticle properties, drug release profiles minimizing off-target effects. Multifunctional integrate with chemotherapy, immunotherapy, or photothermal synergistic treatment approaches that outcomes reduce resistance. Biomimetic nanocarriers, including exosome-mimicking systems cell-membrane-coated nanoparticles, improve circulation time, evasion, targeted tumor delivery. These collectively precision, efficiency, therapies. The scope novelty lie their ability overcome primary barriers while paving way clinically viable solutions. provides comprehensive analysis latest developments fabrication, preclinical studies, assessments. By integrating multifunctionality, biomimicry, holds immense potential future therapy.

Language: Английский

Citations

0
High‐Efficiency Ocular Delivery of Brain‐Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma DOI
Yuheng Cao, Xue Yin,

Lanrong Wu

et al.

Advanced Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 13, 2025

Abstract Glaucoma is a retinal neurodegenerative disease characterized by progressive apoptosis of ganglion cells (RGCs) and irreversible visual impairment. Current therapies rarely offer direct protection for RGCs, highlighting the need new neuroprotective approaches. Although viral delivery brain‐derived neurotrophic factor (BDNF) has shown potential, concerns about inflammation limited applicability persist. Meanwhile, non‐viral vectors remain inefficient in vivo ocular gene delivery. Here, highly biocompatible nanoplatform—PBAE‐PLGA‐Oligomycin‐pBDNF nanoparticles (PPOB NPs) reported—that co‐delivers oligomycin (an ATP inhibitor) BDNF plasmid to Müller vivo. This nanoplatform attains an unprecedented transfection efficiency 64.26% cells, thereby overcoming limitations monotherapeutic approaches that fail inhibit overproduction attendant inflammatory responses. In chronic hypertension rat model, effectively mitigated RGC damage suppressing cell hyperactivation excessive production under elevated intraocular pressure. Concurrently, it synergistically enhanced expression achieving robust RGCs preservation optic nerve function. These findings underscore promise PPOB NPs as dual‐functional platform, featuring high biocompatibility efficient delivery, multifaceted against glaucoma other diseases.

Language: Английский

Citations

0